YSL15 Antibody

What is hIL15-ABD and how does it differ from wild-type IL-15?

hIL15-ABD is a recombinant fusion protein composed of human interleukin-15 (hIL15), an albumin binding domain (ABD), and a hexahistidine tag (his6). Unlike wild-type hIL15, which suffers from poor pharmacokinetic properties due to its short half-life, hIL15-ABD demonstrates significantly enhanced pharmacokinetic parameters. The albumin binding domain allows the fusion protein to bind to serum albumin, substantially extending its circulation time in vivo. Research demonstrates that hIL15-ABD has more than 20-fold increase in biological half-life and 80-fold increase in area under curve (AUC) compared to wild-type hIL15 .

What are the primary mechanisms of action for hIL15-ABD in cancer immunotherapy?

hIL15-ABD functions through multiple immunomodulatory mechanisms:

• Enhancement of CD8+ T cell and NK cell proliferation and cytotoxic activity

• Reduction of immunosuppressive cell populations (MDSCs and Tregs)

• Suppression of immunosuppressive factors such as VEGF, IDO, and FOXP3

• Increased production of effector cytokines like IFN-γ and IL-2 by activated immune cells

• Synergistic effects with checkpoint inhibitors such as anti-PD-L1 antibodies

These mechanisms collectively create a favorable immune microenvironment for anti-tumor responses, significantly enhancing both innate and adaptive immune functions against cancer cells .

What animal models are most appropriate for evaluating hIL15-ABD efficacy?

Based on published research, CT26 murine colon cancer and B16-F10 murine melanoma models have proven to be effective systems for evaluating hIL15-ABD. These models allow researchers to assess not only tumor growth inhibition but also detailed immunological parameters. When designing experiments, consider:

• Tumor cell line selection (CT26 for colon cancer, B16-F10 for melanoma)

• Appropriate dosing schedule (typically 5 μg per injection for mice models)

• Inclusion of proper controls (untreated, wild-type hIL15, and monotherapy groups)

• Comprehensive immune cell analysis from tumor-draining lymph nodes (TDLN), spleen, bone marrow, and tumor tissue

• Evaluation of both monotherapy and combination therapy approaches

What are the recommended dosing protocols for hIL15-ABD in preclinical research?

When designing dosing protocols, research indicates that 5 μg (approximately 0.24 nanomoles) of hIL15-ABD per injection is effective in murine models. This dosing regimen has demonstrated superior tumor growth inhibition compared to equivalent injections of wild-type hIL15 (0.36 nanomoles). The significant enhancement in pharmacokinetic properties of hIL15-ABD allows for less frequent dosing while maintaining therapeutic efficacy. Researchers should monitor body weight throughout treatment, as weight loss has been observed with unmodified hIL15 but not with hIL15-ABD, suggesting improved tolerability of the fusion protein .

What flow cytometry panels are recommended for comprehensive immune monitoring of hIL15-ABD therapy?

For thorough immune monitoring of hIL15-ABD therapy, researchers should implement multi-parameter flow cytometry panels that assess:

• T cell populations: CD4+/CD25+/FOXP3+ (Tregs), CD8+ T cells, and their activation status (IFN-γ, IL-2)

• NK cell populations: CD3-/CD49b+, CD3-/CD335+, CD3-/NK1.1+, and combinations of these markers

• Myeloid-derived suppressor cells (MDSCs): CD11b+/Gr-1+

• Functional markers: Intracellular cytokines (IFN-γ, IL-2) and cytotoxic molecules (granzyme B)

Samples should be collected from tumor-draining lymph nodes (TDLN), spleen, bone marrow, and tumor tissues to comprehensively evaluate the systemic and local immune effects of therapy .

How should researchers evaluate the tumor microenvironment (TME) changes induced by hIL15-ABD?

Effective evaluation of TME changes requires a multi-modal approach:

• Immunohistochemistry (IHC) staining of tumor sections for:

  • T cell markers (CD8, granzyme B)

  • NK cell markers (CD49b)

  • Cytokine production (IFN-γ)

• Flow cytometry analysis of tumor-infiltrating lymphocytes

• Quantification of immunosuppressive factors in serum and tumor tissue:

  • VEGF levels in serum

  • IDO expression in tumor tissue

  • FOXP3 expression (marker for Tregs)

• Analysis of cytokine profiles in tumor tissue and serum

This comprehensive approach allows researchers to fully characterize how hIL15-ABD modulates the TME toward an anti-tumor phenotype .

What is the scientific rationale for combining hIL15-ABD with checkpoint inhibitors?

The rationale for combination therapy stems from complementary mechanisms of action:

• hIL15-ABD increases the number and activity of effector immune cells (CD8+ T cells and NK cells)

• Checkpoint inhibitors (e.g., anti-PD-L1) remove inhibitory signals that suppress these effector cells

• hIL15-ABD reduces immunosuppressive cell populations (Tregs, MDSCs) that may limit checkpoint inhibitor efficacy

• The combination creates a more favorable cytokine milieu in the TME

Research demonstrates that this combination approach results in synergistic anti-tumor effects superior to either monotherapy, with significant enhancement of both innate and adaptive immune responses against tumors .

What experimental protocols are recommended for evaluating hIL15-ABD and anti-PD-L1 combination therapy?

When designing combination therapy experiments, researchers should:

• Include four treatment groups: control, hIL15-ABD monotherapy, anti-PD-L1 monotherapy, and combination therapy

• Use established dosing regimens (e.g., 5 μg of hIL15-ABD per injection)

• Schedule treatments to allow for potential synergistic effects (concurrent administration)

• Assess tumor growth kinetics over time

• Perform comprehensive immune profiling as described in section 3

• Evaluate survival outcomes when feasible

• Analyze serum for cytokine production and immunosuppressive factors

This approach enables thorough assessment of synergistic effects between hIL15-ABD and checkpoint inhibitors .

What are the main technical challenges in producing and purifying functional hIL15-ABD?

Production of hIL15-ABD involves several technical challenges:

• Expression system: While E. coli can be used for expression, the protein requires proper refolding to achieve biological activity

• Purification complexity: The fusion protein requires specialized purification strategies to maintain structural integrity

• Activity verification: Confirmation of both albumin binding and IL-15 bioactivity is essential

• Stability considerations: The fusion protein must maintain stability under storage and experimental conditions

Researchers can address these challenges by using established protocols for bacterial expression, implementing careful refolding procedures, and confirming functionality through both albumin binding assays and bioactivity tests such as CTLL-2 proliferation and STAT5 phosphorylation assays .

How can researchers confirm the bioactivity of purified hIL15-ABD preparations?

To confirm bioactivity of hIL15-ABD preparations, researchers should implement a multi-assay approach:

• CTLL-2 cell proliferation assay: This IL-2/IL-15-dependent cell line provides a sensitive readout of hIL15-ABD bioactivity

• Phospho-STAT5 detection: Western blotting or flow cytometry to assess STAT5 phosphorylation in responsive cell lines

• Albumin binding assay: To confirm functionality of the ABD domain

• NK cell activation assay: Measuring IFN-γ production or cytotoxicity of NK cells in response to hIL15-ABD

• In vivo pharmacokinetic analysis: Confirming extended half-life compared to wild-type hIL15

These complementary assays ensure that the purified protein maintains both structural integrity and functional activity .

What mechanisms explain the superior anti-tumor efficacy of hIL15-ABD compared to wild-type IL-15?

The superior efficacy of hIL15-ABD over wild-type IL-15 stems from multiple mechanisms:

• Extended biological half-life (>20-fold increase) and improved pharmacokinetics (80-fold increase in AUC)

• More effective reduction of immunosuppressive cell populations:

  • Significant decrease in MDSCs in spleen and bone marrow

  • More potent reduction of Tregs in tumor-draining lymph nodes and spleen

• Enhanced expansion of effector populations:

  • Approximately double the percentage of CD8+ T cells compared to control

  • Superior NK cell activation across multiple NK cell markers

• Lower toxicity profile, as evidenced by stable body weight compared to weight loss observed with wild-type hIL15

These advantages collectively contribute to the enhanced anti-tumor efficacy observed in preclinical models .

How does hIL15-ABD modulate the tumor microenvironment differently from other IL-15-based therapeutics?

hIL15-ABD demonstrates distinct TME modulation compared to other IL-15 therapeutics:

• Comprehensive immune cell modulation: Unlike some IL-15 superagonists that primarily expand NK cells, hIL15-ABD effectively enhances both NK and CD8+ T cell populations while reducing immunosuppressive cells

• Balanced cytokine induction: hIL15-ABD induces balanced production of effector cytokines (IFN-γ, IL-2) without triggering cytokine storm concerns associated with some IL-15 therapies

• Synergistic TME remodeling: When combined with anti-PD-L1, hIL15-ABD demonstrates enhanced ability to:

  • Increase tumor infiltration by CD8+ T cells and NK cells

  • Elevate granzyme B expression in tumors

  • Reduce VEGF production

  • Diminish Treg and MDSC accumulation

These distinctive properties make hIL15-ABD particularly attractive for rational combination immunotherapy strategies .

What strategies can address variability in immune responses to hIL15-ABD across different tumor models?

Researchers may encounter variability in responses across tumor models due to differences in immunogenicity, tumor growth kinetics, and baseline immune infiltration. To address these challenges:

• Perform baseline immune profiling of each tumor model to understand pre-existing immune status

• Adjust dosing schedules based on tumor growth kinetics (faster-growing tumors may require earlier intervention)

• Consider tumor-specific combination strategies (e.g., adding anti-CTLA-4 for poorly immunogenic tumors)

• Implement consistent sample collection timing relative to treatment administration

• Use larger group sizes to account for biological variability

• Consider genetic modification of tumor lines to express tracking antigens or reporters

These approaches can help standardize experimental conditions and reduce variability across different tumor models .

How can researchers optimize tissue collection and processing to accurately assess hIL15-ABD effects on immune cells?

Proper tissue collection and processing are critical for accurate assessment of hIL15-ABD immunomodulatory effects:

• Standardize collection timepoints: Collect tissues at consistent intervals post-treatment (e.g., 24h, 72h, 7 days)

• Implement rapid processing: Minimize time between tissue harvest and processing to maintain cell viability

• Use enzymatic digestion for tumor samples: Optimize collagenase/DNase protocols for each tumor type

• Include viability dyes in flow cytometry panels: Exclude dead cells that may bind antibodies non-specifically

• Employ consistent gating strategies: Establish and maintain consistent flow cytometry analysis parameters

• Process matched tissues from all experimental groups simultaneously: Minimize batch effects

• Consider single-cell preservation methods for complex analyses (e.g., scRNA-seq)

These methodological considerations ensure robust and reproducible assessment of hIL15-ABD's effects on immune cell populations .

What are promising strategies for further enhancing hIL15-ABD efficacy through rational drug combinations?

Beyond anti-PD-L1 combinations, several promising strategies warrant investigation:

• Combining with other checkpoint inhibitors (anti-CTLA-4, anti-LAG3, anti-TIM3)

• Addition of targeted therapies that promote immunogenic cell death

• Combination with CAR-T cell therapy to enhance persistence and efficacy

• Integration with cancer vaccines to prime tumor-specific T cells that can be expanded by hIL15-ABD

• Combination with agents targeting the tumor vasculature or stromal components

• Sequential therapy approaches (e.g., radiation followed by hIL15-ABD + checkpoint inhibition)

These combinatorial approaches may further enhance the anti-tumor efficacy of hIL15-ABD by addressing multiple aspects of tumor immune evasion simultaneously .

What biomarkers might predict response to hIL15-ABD therapy in translational research?

Identifying predictive biomarkers will be crucial for clinical translation. Promising biomarker strategies include:

• Baseline immune infiltrate assessment (CD8+ T cell and NK cell density)

• Immunosuppressive cell quantification (MDSCs, Tregs) before treatment

• PD-L1 expression levels in tumor and immune cells

• Tumor mutational burden and neoantigen load

• Specific cytokine profiles in serum and tumor tissue

• Gene expression signatures associated with IL-15 responsiveness

• Pharmacodynamic markers of IL-15 pathway activation

These biomarker approaches can help identify patient populations most likely to benefit from hIL15-ABD therapy and optimize treatment strategies for maximum efficacy .